Gene

IRS2

insulin receptor substrate 2

Explore in graph →CI-GENE-00006338HGNC:6126 ENSG00000185950 NCBI 8660 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
IRS2 Amplification2
Capivasertib	Malignant Prostate Neoplasm	Predictive	C	Supports Resistance	2	submitted	EID10764 Phase 2 trial of capivasertib in solid cancer patients with AKT1/2/3 alterations. One patient with metastatic prostate cancer and in-frame AKT2 L78_Q79ins(HANTFVIRCL) that previously progressed on enz… (full text at CIViC) PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC	civic
Dual IGF-1R/InsR Inhibitor BMS-754807	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID7075 Cell lines with IRS2 copy number gain had higher levels of ligand-stimulated activation of IGF-1R and AKT. IRS2 siRNA knockdown reduced IRS2 protein expression levels and decreased sensitivity to BMS-… (full text at CIViC)

Cohorts

Alteration frequency by cohort (114)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved114 cohort rows (showing 14, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018) hcc_mskimpact_2018	Hepatocellular Carcinoma	Ssm

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.